These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23797954)

  • 1. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
    Lewis RA; McDermott MP; Herrmann DN; Hoke A; Clawson LL; Siskind C; Feely SM; Miller LJ; Barohn RJ; Smith P; Luebbe E; Wu X; Shy ME;
    JAMA Neurol; 2013 Aug; 70(8):981-7. PubMed ID: 23797954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
    Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
    Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
    Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
    Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.
    Verhamme C; de Haan RJ; Vermeulen M; Baas F; de Visser M; van Schaik IN
    BMC Med; 2009 Nov; 7():70. PubMed ID: 19909499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
    Pareyson D; Schenone A; Fabrizi GM; Santoro L; Padua L; Quattrone A; Vita G; Gemignani F; Visioli F; Solari A;
    Pharmacol Res; 2006 Dec; 54(6):436-41. PubMed ID: 17029975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
    Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D
    Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropathy progression in Charcot-Marie-Tooth disease type 1A.
    Shy ME; Chen L; Swan ER; Taube R; Krajewski KM; Herrmann D; Lewis RA; McDermott MP
    Neurology; 2008 Jan; 70(5):378-83. PubMed ID: 18227419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.
    Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S
    PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.
    Toth C
    Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
    Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
    Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.
    Fridman V; Sillau S; Acsadi G; Bacon C; Dooley K; Burns J; Day J; Feely S; Finkel RS; Grider T; Gutmann L; Herrmann DN; Kirk CA; Knause SA; Laurá M; Lewis RA; Li J; Lloyd TE; Moroni I; Muntoni F; Pagliano E; Pisciotta C; Piscosquito G; Ramchandren S; Saporta M; Sadjadi R; Shy RR; Siskind CE; Sumner CJ; Walk D; Wilcox J; Yum SW; Züchner S; Scherer SS; Pareyson D; Reilly MM; Shy ME;
    Neurology; 2020 Mar; 94(9):e884-e896. PubMed ID: 32047073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The application of scales and characteristics of disability in the common genotypes of Charcot-Marie-Tooth disease].
    Liu X; Zhang RX; Liu L; Xie YZ; Lin ZQ; Zhao Q; Cao WQ; Zhu XY; Li XB
    Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(2):131-136. PubMed ID: 33455129
    [No Abstract]   [Full Text] [Related]  

  • 17. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
    Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
    Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.
    Murphy SM; Herrmann DN; McDermott MP; Scherer SS; Shy ME; Reilly MM; Pareyson D
    J Peripher Nerv Syst; 2011 Sep; 16(3):191-8. PubMed ID: 22003934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
    Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
    Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employment status of patients with Charcot-Marie-Tooth type 1A.
    Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
    Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.